Hosted by Dr. Yan Leyfman, the MedNewsWeek Keynote, in partnership with OncoDaily TV, features Dr. Melvin L. K. Chua, Head of the Department of Head & Neck and Thoracic Radiation Oncology and Senior Consultant at the National Cancer Centre Singapore.
In this comprehensive and forward-looking session, Dr. Melvin L. K. Chua explores how precision radiation strategies, particularly proton beam therapy are transforming outcomes in nasopharyngeal carcinoma (NPC), a disease highly prevalent in Asia.
From the early days of 2D radiotherapy planning to modern IMRT and advanced pencil beam scanning proton therapy (IMPT), this keynote highlights both the scientific innovation and the clinical artistry required to optimize tumor control while minimizing toxicity.
Dr. Melvin L. K. Chua also presents newly published international consensus guidelines in The Lancet Oncology on target volume delineation for NPC — a landmark global collaboration endorsed by major oncology societies worldwide.
Key discussion points:
- The Evolution of Radiotherapy: From 2D Planning to Proton Therapy Why
- Dose Precision Is Critical in Locally Advanced NPC
- IMRT vs IMPT: Clinical Outcomes & Toxicity Profiles
- Reducing Xerostomia, Dysgeusia & Dysphagia with Proton Therapy
- Singapore’s Proton Experience: Early Clinical Data
- The Art of Contouring: Why Delineation Defines Success
- Post-Induction Chemotherapy Planning Strategies
- High, Intermediate & Low-Risk CTV Framework Explained
- Selective Neck Irradiation & Thyroid Sparing
- International Consensus Guidelines Published in The Lancet Oncology
- The Future of Radiotherapy: Collaboration, Trials & Personalization